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Schizophrenia is an illness where the clinical signs and
symptoms, course, and cognitive characteristics are well
described. Successful pharmacological treatments do exist,
even though they are likely palliative. However, this broad
knowledge base has not yet led to the identification of its
pathophysiology or etiology. The risk factors for schizo-
phrenia are most prominently genetic, and scientists antic-
ipate that contributions from the new genetic informa-
tion in the human genome will help progress towards
discovering a disease mechanism. Brain-imaging tech-
niques have opened up the schizophrenic brain for direct
inquiries, in terms of structure, neurochemistry, and func-
tion. New proposals for diagnosis include grouping schiz-
ophrenia together with schizophrenia-related personality
disorders into the same disease entity, and calling this
schizophrenia spectrum disorder. New hypotheses of
pathophysiology do not overlook dopamine as playing a
major role, but do emphasize the participation of inte-
grative neural systems in the expression of the illness and
of the limbic system in generating symptoms. Critical
observations for future discovery are likely to arise from
molecular genetics, combined with hypothesis-generat-
ing experiments using brain imaging and human post-
mortem tissue.
chizophrenia is a chronic recurring psychotic
illness that characteristically begins in young adult years
and lasts a lifetime.
1,2 Prodromal symptoms often pre-
cede the acute psychosis, including cognitive dysfunc-
tion and negative symptoms.
3 Whether schizophrenia
represents a single illness or is a syndromal diagnosis is
still unknown,and data indicating how we should define
disease subgroups are still required.
4,5 Because the dis-
ease has affected humans for millennia,clinicians know
a considerable amount about the clinical characteris-
tics,onset,response to interventions,and tissue response
characteristics of persons with the illness.
6-8 Here, we
will review what is known about schizophrenia and
speculate on the potential meaning of this constellation
of observations.
Schizophrenia: 
the clinical condition
Psychosis
The defining features of a schizophrenia diagnosis are
hallucinations, delusions, paranoia, and thought disor-
der; these experiences are manifest in multiple sensory
modalities and include abnormalities in all aspects of
thought, cognition, and emotion (Table I, see next
page).
4,9,10The psychotic symptoms often have an insidi-
ous onset, and are characterized by a failure of logic,
customary associations,intent,and the organization that
usually accompanies human thought. It is not the loss
but rather the malfunction of these functions that char-
acterizes psychosis. Moreover, these features can fluc-
tuate in intensity and across sensory substrates through-
out the illness.
11
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State of the artOther disease features
The advent of antipsychotic drugs that are effective in
the treatment of psychosis has exposed aspects of schiz-
ophrenia that were often overlooked when the florid
presentation was untreated.These aspects include cog-
nitive dysfunction and primary negative symptoms.
1,12-14
Cognitive symptoms will be discussed later in their own
section. Primary negative symptoms include manifesta-
tions of alogia,anhedonia,and asociality,and are seen as
part of the illness complex in many persons with schizo-
phrenia.
4Whether these symptoms are generated in the
central nervous system (CNS) along with the process
that results in the psychosis, or whether they have their
own pathophysiology,is not yet known and opinions dif-
fer widely as to the answer. In optimally treated outpa-
tient populations in which psychosis is at least partially
controlled, analyses show that negative symptoms and
cognitive dysfunction contribute more strongly to over-
all psychosocial disability than do residual positive
symptoms.
15Therefore,targeting these symptomatic dys-
functions for treatment could powerfully improve out-
come for affected individuals.
Course
Schizophrenia characteristically begins in young adult
years and lasts throughout life, with only occasional
recovery.
11,16 It is the case,however,that childhood-onset
and adult/elderly-onset cases occur. The initial years of
illness are often the most symptomatic and include
severe psychosocial deterioration.Middle-aged years are
more benign;and in the elderly,frank symptom recovery
has been described.
17-19 Within this simplistic framework,
episodes of psychosis regularly occur. One can formu-
late schizophrenia as a disease of childbearing years,even
though elderly persons with the illness still retain symp-
toms. Differing interactions between schizophrenia and
aging have been reported. Some clinical samples show
symptom improvement accompanied by psychosocial
stability with aging,whereas other clinical samples show
a precipitous age-related deterioration with loss of cog-
nitive function and frank dementia.
20 Questions of late-
life outcome in schizophrenia remain to be addressed.
Risk factors for schizophrenia
Genetics
A risk for schizophrenia is inherited.
21 Twin studies have
been pivotal in verifying a genetic predisposition.
22,23 The
more closely one is related to an individual with schizo-
phrenia, the greater the risk of contracting the illness
(Table II).The prevalence in the general population is 1%.
The disease occurs in all cultures and people around the
world (with rare exceptions),and with similar genetic risk
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Selected abbreviations and acronyms
ACC anterior cingulate cortex
CAT computerized axial tomography
CNS central nervous system
EEG electroencephalography
fMRI functional magnetic resonance imaging
IEG immediate early gene
MRI magnetic resonance imaging
NMDA N-methyl-D-aspartate
PCP phencyclidine
rCBF regional cerebral blood flow
SPM statistical parametric mapping
VOI volume of interest
Positive symptoms
Hallucinations, delusions, reality distortion
Negative symptoms
Anhedonia, asociality, alogia
Cognitive deficits
Attention, working memory, executive functions
Neurophysiologic changes
Eye movements, evoked potentials (P50, P300)
Table I. Symptoms of schizophrenia.
General population  1%
Second-degree relative  2.5% 
Parent 3.8%
Sibling 8.7%
Child, 1 parent  12%
Child, 2 parents  30%–40%
Twin, monozygotic  40%–50%
Table II. Genetic risk for schizophrenia in terms of prevalence estimates.341
estimates.The monozygotic twin of a person with schizo-
phrenia,who shares the same genome,has a 40% to 50%
risk of contracting the illness;this number represents not
only a 50% genetic risk, but also a 50% nongenetic risk,
each operating in the manifestations of the illness.
Association studies in schizophrenia suggest that schizo-
phrenia is a complex multigenetic disorder. Many genes
associated with the illness have been identified in the dif-
ferent studies. Each risk factor confers a small risk, with
the genetic factors being the most potent.Risk factors are
thought to be multiplicative.
24-27
Pre- or perinatal events
Catastrophic pre- or perinatal events, like exposure to
famine, radiation, or a maternal viral illness, especially
during the second trimester, are significant risk factors
for schizophrenia.These early events do not have as much
predictive power as the genetic factors,but can nonethe-
less explain significant variance.
28 Perinatal events like
toxemia and hypoxia at birth are risk factors for schizo-
phrenia,
29 as is a winter birth.
30 It should be emphasized
that most individuals who experience pre- or perinatal
events of this sort or a winter birth do not ultimately con-
tract schizophrenia. So the neural consequences that
derive from these pre- or perinatal conditions do not
inevitably lead to schizophrenia.These conditions, how-
ever, may combine with other precipitating factors to
facilitate illness onset.
Factors during childhood and adolescence
Environmental factors have also been suggested as risks for
schizophrenia.These most prominently include the use of
marijuana (and possibly other forms of drug dependence,
although this is less rigorously documented). Trauma is
often mentioned as a proximal risk factor for the illness,
although the actual documentation for this is soft.The rear-
ing environment characterized by emotion and stress is
also often identified as a precipitant for schizophrenia.
Psychological and electrophysiologic 
characteristics of schizophrenia
Cognitive dysfunction
Patients with schizophrenia characteristically perform
more poorly on neuropsychological tasks than normal
subjects.
31 No cognitive domain is entirely spared and
abnormalities are highly intercorrelated within a single
individual.
32This performance defect is explained as both
(i) a consequence of ongoing psychotic symptoms, early
disease onset,and/or chronic institutionalization;and (ii)
a set of specific deficits associated with the pathophysi-
ology of schizophrenia.
12,13,33-35 Persons with the illness
show particular inabilities when performing tasks asso-
ciated with attention,memory,and executive function.
36
In monozygotic twins discordant for schizophrenia,the
schizophrenic twin inevitably performs more poorly on
tests of intelligence, memory, attention, verbal fluency,
and pattern recognition than the nonschizophrenic
twin.
33When tested,the nonschizophrenic twin only dif-
fers from normal individuals on the basis of a reduc-
tion in “logical memory,” as measured on the Wechsler
scale and in Trails A performance. In addition, persons
with schizophrenia consistently perform poorly on tasks
that require sustained attention,sometimes called vigi-
lance.
37 Also,“working memory” or the mechanism by
which task-relevant information is kept active for brief
periods (ready for quick retrieval) is deficient in schiz-
ophrenia.
38
Cognitive scientists have suggested that the widespread
disturbances in attention, memory, and language are
associated with a change in the “internal representa-
tion”of contextual information.
39They also have specu-
lated that it is the CNS connection between “cognitive
modules”(ie,the circuitry) that may be altered in schiz-
ophrenia, but not the internal organization of the mod-
ule itself.
40Whatever the model turns out to be,the cog-
nitive defects of schizophrenia are consistent with a
widespread disruption in cerebral function and cogni-
tion. Also notable is the observation that in any single
individual with the illness, symptoms fluctuate and
change over time, making it hard to invoke permanent
cerebral changes in neuronal function or circuitry as the
basis of these cerebral abnormalities.
Neurophysiological dysfunction
Measures of brain response to graded external stimuli
have been characterized in schizophrenia and used to
postulate its pathophysiology. These measures include
primary eye movements in response to a smooth pursuit
stimulus and electroencephalography (EEG) wave char-
acteristics in response to a sensory stimulus. Smooth
pursuit movements are slow eye movements used to
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track a small moving object.
41 Normal subjects locate
the moving target on their retinal fovea and move their
eye with the target, following its smooth rate.The nor-
mal eye and brain use predictive smooth pursuit move-
ments with occasional predictive saccades to follow a
moving target efficiently.
42 Persons with schizophrenia
have abnormal smooth pursuit eye movements, and
these are not explained by psychosis or medication.
43,44
Moreover,many nonpsychotic family members of schiz-
ophrenics also show abnormal smooth pursuit move-
ments, especially if they have a diagnosis of schizo-
phrenia spectrum disorder.
45-47 It has been hypothesized
that the cerebral defect underlying abnormal eye track-
ing in schizophrenia is one of motion processing,
48 in
the link between motion information and eye move-
ments
49 or in the holding of the motion information in
short-term memory.
46,50The latter formulation implicates
the posterior parietal cortex and/or the middle frontal
cortex in abnormal eye movements. In addition to
smooth pursuit movements, saccadic eye movements
have also been noted to be abnormal in schizophre-
nia.
45,51,52 The nature of this abnormality also implicates
frontal cortical dysfunction in the illness.
53
Signal-averaged EEG changes that are time-locked to
sensory or cognitive events (evoked potentials) repre-
sent measures of individual information processing,
independent of a behavioral response. Elements of
these evoked potentials are abnormal in schizophrenia,
specifically the P300 element and the P50 wave. The
P300 amplitude is consistently reduced in schizophre-
nia.
54,55 The P50 wave after a second auditory stimulus in
schizophrenia is also abnormal,insofar as its amplitude
is the same after the second as after the first auditory
stimulus (instead of diminished).
56 Investigators have
used these kinds of measurements to support the con-
cept of abnormal sensory gating in schizophrenia and its
genetic association.
57
Schizophrenia 
spectrum disorders
There is an emerging formulation from several labora-
tories that schizophrenia is part of a larger set of dis-
orders called schizophrenia spectrum disorders or
schizotaxia;these disorders are related to each other in
terms of genetics,symptom expression,cognitive char-
acteristics, and, potentially, pathophysiology. Schizo-
phrenia itself may be the most severe manifestation of
the class and characterized by the most flagrant psy-
chosis and the worst psychosocial function (Figure 1).
But impairment at multiple levels and schizophrenia-
like symptoms span the entire spectrum group.
Approximately 20% of family members of an individ-
ual with schizophrenia have spectrum manifestations.
Moreover, approximately 20% of persons with spec-
trum manifestations have symptoms that are severe
enough to impair work function and may benefit from
antipsychotic treatment (G.Thaker, personal commu-
nication).
First-degree relatives of schizophrenic probands may
display many of the cognitive symptoms characteristic
of schizophrenia, only without the florid psychosis.
These include task-related impairments in attention,
language comprehension, verbal fluency, verbal mem-
ory, and spatial working memory. It is suspected that
these cognitive disturbances in relatives occur predom-
inantly in those with spectrum symptoms, however
more study is required.Some adjustments in the criteria
for spectrum disorder (ie, loosening) may be required
for that diagnosis to capture all affected persons.
Considering spectrum disorders as a relevant diagnos-
tic category adds 5% to the prevalence of the schizo-
phrenia diagnosis. Perhaps up to 20% of the spectrum
group is impaired enough to require treatment.These
observations may serve to broaden our concepts of
schizophrenia, its manifestations, and beneficial treat-
ment opportunities.
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Figure 1. Schizophrenia spectrum disorders. The prevalences of schiz-
ophrenia and schizophrenia-related personality disorders in the general
population are 1% and 5%, respectively; the prevalence of both
together is 6%.
1%
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Schizophrenia
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Brain structure 
and function in schizophrenia
Brain structure
One of the first discoveries in schizophrenia using mod-
ern imaging technologies was structural,first with com-
puterized axial tomography (CAT) scanning and later
with magnetic resonance imaging (MRI).Johnstone and
Crow
58 then Weinberger
59 described enlarged cerebral
ventricles in persons with the illness.Over time,an over-
whelming number of confirmations have accumu-
lated.
59,60Ventricular size is a crude and nonspecific indi-
cation of cerebral dysfunction, and possibly only an
epiphenomenon of this illness. However, this observa-
tion has served to redirect interest toward examining
the brain for abnormal characteristics in persons with
the illness.
As structural imaging techniques have developed higher
resolution,additional volumetric differences in the schiz-
ophrenic brain have been identified.Several laboratories
focusing on the superior temporal gyrus have reported
volume decreases in schizophrenia and a correlation
between the volume changes and clinical characteristics
of the illness.
61,62 The medial temporal cortex, including
parahippocampal,entorhinal,and hippocampal cortex,is
also reduced in size in schizophrenia. This size reduc-
tion is only of the order of 5%, but is consistent across
laboratories and subject populations. Csernansky has
gone on to identify hippocampal shape irregularities in
schizophrenia.
63 Some laboratories note middle frontal
cortical volume reductions in negative-symptom schizo-
phrenia
64 and volume alterations in the pulvinar region
of the posterior thalamus in persons with the illness.
65
These alterations are thought to be in vivo reflections of
regional cellular pathology in the illness.
Brain function
When functional techniques for studying human brain
became available, they were quickly applied to schizo-
phrenia.Ingvar
66 was the first to note reduced prefrontal
cortical blood flow in schizophrenia. Subsequent early
studies
8,64,67,68 served to focus scientific interest on the
frontal cortex;this was a great advantage to the scientists
who later followed up these ideas.Subsequent functional
imaging studies have noted an antipsychotic drug effect
in prefrontal regions (reduced neuronal activity)
69,70 and
an influence of negative symptoms in prefrontal and
inferior parietal cortex.
8,71
Current imaging approaches in schizophrenia utilize
both structural scanning and neurochemical (see Laru-
elle
72 in this issue) and functional methodologies. The
functional approaches are based on advances in the
understanding of normal cognition also derived from
functional imaging data.Since the introduction of func-
tional imaging techniques over 20 years ago,using either
glucose metabolism or blood flow as the functional end
points,several technical methodological principles have
developed. Functional “stimulation” using either a psy-
chological task or a centrally active drug adds an impor-
tant parameter to such an examination. Drug effects,
especially antipsychotic compounds, are recognized as
potentially informative in deciding on disease-related
(compared with drug-related) differences between schiz-
ophrenia and normal test populations.Studies with this
focus, in addition to functional increases in the basal
ganglia, also noted alterations in delimited cerebral
areas, especially reductions in metabolism or regional
cerebral blood flow (rCBF) in the frontal cortex (ante-
rior cingulate and middle frontal gyrus).
73 Since the
effect of psychological tasks on rCBF has been particu-
larly informative in exploring normal brain function,
hierarchical subtraction techniques are now being
applied to schizophrenia.This approach has been prob-
lematic because of the altered performance levels
between persons with schizophrenia and normal con-
trols, which introduce a potential confounding element
into the functional assessment during performance.
Recent utilization of variable performance tasks have
contributed to a solution here.
69 
rCBF studies in schizophrenia have been used to iden-
tify CNS regions of abnormal function in the illness.
While no single region has been identified in all labora-
tories,several distinct abnormalities are prominent and
suggest,above all,the possibility that an abnormality of
several systems in the brain underlies the illness. Ini-
tially,the middle frontal cortex (dorsolateral prefrontal
region) was identified as abnormal in schizophrenia
66
and has subsequently been tied to manifestations of pri-
mary negative symptoms in the illness.
8,64,71 More
recently, laboratories have focused on the anterior cin-
gulate cortex (ACC)
8,73,74 and the hippocampus
75 as being
potentially primarily involved in the psychotic process.
A role of the basal ganglia cannot be ruled out.
76
Functional magnetic resonance imaging (fMRI) studiesof rCBF have produced a variety of results, often with
conflicting data,possibly because of the augmented spa-
tial resolution of this methodology.For example,during
studies involving performance of a motor task in three
different laboratories,subjects with schizophrenia were
found to show no differences from normal subjects in
rCBF,
77,78 or increased rCBF,
79 or decreased rCBF
80 in
the sensorimotor cortex. Each of these studies sug-
gested the potential of an interactive effect with previ-
ous or current antipsychotic medication.Tasks demand-
ing higher-order cognitive functions,such as attention or
working memory,have also resulted in conflicting data.
For example,one study found an increase in frontal cor-
tical rCBF in schizophrenia compared with healthy per-
sons with a working memory task, whereas two other
laboratories reported decreases in this area with a sim-
ilar task. Additional studies in this area will hopefully
define the subject variables, performance demands, or
the illness phase contribution(s) that are important for
an explanation of these discrepancies. Use of fMRI is
rapidly increasing in all academic centers, and so
progress will not lag in this area.
The functional imaging studies from our laboratory
have compared persons with schizophrenia with
matched healthy individuals while performing an audi-
tory recognition task in an overlearned, practiced con-
dition, with normals with a similar task performance.
The two groups of volunteers performed similarly on
accuracy and tone interval. In this situation, the volun-
teers with schizophrenia showed rCBF differences from
the normals only in the ACC/medial frontal cortex.
Those schizophrenic volunteers who had a similar per-
formance to normal subjects on the basis of accuracy,
but required wide tone disparities to do so,had not only
rCBF reductions in the ACC,but also flow reductions in
the middle frontal and inferior frontal cortex (Figure
2). These observations invoke the concept of a circuit
failure,possibly of limbic cortex,and affect those areas
of prefrontal cortex whose functions are highly influ-
enced by the ACC.
Some of our functional imaging studies have focused
on the hippocampus. Because statistical parametric
mapping (SPM) analytic techniques rely on group
average data and because the hippocampus is both
small and variably located in humans, magnetic reso-
nance–guided hand sampling producing volumes of
interest (VOIs) is necessary to adequately represent
the structure. We used magnetic resonance–guided
individual VOI image sampling and made several
interesting observations about hippocampal function.
First, in a practiced, overlearned auditory recognition
task, the hippocampus remains uninvolved with task
performance with respect to changes in rCBF, in both
normal volunteers and those with schizophrenia.This
confirms that novelty and/or learning is necessary for
hippocampal activation. Second, rCBF in the schizo-
phrenic hippocampus is greater than in the normal
hippocampus bilaterally,and across different task con-
ditions. Third, the noncompetitive N-methyl-D-aspar-
tate (NMDA) antagonist ketamine reduces rCBF in
the schizophrenic hippocampus,but not in the normal
hippocampus, over a 30-min time course. This last
observation suggests that the affected hippocampus,
which already evidences elevated rCBF in the med-
ication-free state, is more sensitive to glutamatergic
inhibition.This observation is consistent with some of
our other postmortem findings showing reduced
NMDA receptor NR1 subunits in schizophrenia, and
hence potential reductions in the number of functional
NMDA receptors.
State of the art
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SZ normal tone
minus
SZ abnormal tone
Figure 2. Subtraction image at two different brain levels (40 mm and 50
mm above the anterior commissure–posterior commissure [AC-PC] line)
of schizophrenic volunteers (SZ) performing a task. The regional cerebral
blood flow (rCBF) of the schizophrenic volunteers who performed the
task abnormally was subtracted from the rCBF of those who performed
the task just like normals. All the schizophrenic volunteers differed from
the normals only in the anterior cingulate cortex (ACC). The schizo-
phrenic volunteers who performed poorly also had abnormal flow in the
right middle frontal cortex and in the ACC.
Reproduced from reference 81: Holcomb HH, Lahti AC, Medoff DR, Weiler M,
Dannals RF, Tamminga CA. Brain activation patterns in schizophrenic and com-
parison volunteers during a matched-performance auditory recognition task. Am
J Psychiatry. 2000;157:1634-1645. Copyright © 2000, American Psychiatric Asso-
ciation, Inc.Theories of 
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Dopamine
Hypotheses to explain the manifestations of schizo-
phrenia have been posited for centuries. The finding a
half century ago that antipsychotic drugs block
dopamine receptors in brain
82 and thereby reduce psy-
chotic symptoms strongly supported the idea that an
overactive dopaminergic system causes schizophrenia.
Many years and many experiments later, evidence to
support this idea has now been generated using mod-
ern imaging tools.
83 Yet while increased dopamine
release may be associated with the psychotic manifesta-
tions of schizophrenia, there is slim evidence that
dopaminergic abnormalities may be more broadly influ-
ential in cognitive or negative manifestations or in a
broader schizophrenia process.
Neural systems
As knowledge of normal brain function has revealed
intricate and complexly interacting neural systems, so
these ideas have also been applied to schizophrenia.The
work of DeLong
84 has suggested that there are long-
tract pathways between the frontal cortex and subcorti-
cal areas through which the basal ganglia and thalamus
influence the function of the frontal cortex.Since many
of the cognitive and functional abnormalities in schizo-
phrenia involve the frontal cortex and its functions, an
alteration in these feedback systems offers strong face
validity to explain certain symptoms in schizophrenia.
Regions of the frontal cortex project to the caudate or
putamen in segregated, parallel neuronal pathways.
Within the basal ganglia, these projections are propa-
gated to related downstream structures, including spe-
cific thalamic nuclei, and then project back to the dis-
crete frontal cortex regions.Since the basal ganglia have
a diversity of neurotransmitters and modulators,and are
richly innervated by diverse brain structures, there is
ample opportunity within these pathways to capture sig-
nificant regional influence and to subsequently modulate
frontal cortical function. Any abnormality in the
dopaminergic dynamics,
83 the balance of neurotransmit-
ter function in the basal ganglia,
76 or the influence of the
thalamus
65 could alter frontal cortical function through
these pathways.
Neurodevelopmental factors
The idea that schizophrenia is a neurodevelopmental ill-
ness, whose pathology is already set at birth and only
expresses itself as psychosis later, has become popular.
This formulation of illness onset explains the influence
of pre- or perinatal events and the evidence of premorbid
cognitive predictors of illness onset. Nonetheless, the
course of schizophrenia does not conform to that of a
traditional neurodevelopmental illness,like mental retar-
dation,whose symptoms appear at birth.However,it has
been argued that the neural apparatus subserving schizo-
phrenia does not mature until late teens,and cannot fully
express its dysfunction before this.Another caveat is that
there is actually scant biological evidence to support the
neurodevelopmental formulation.Also, it is not the case
that all forms of schizophrenia need to be based on the
same etiology,even if they involve the same pathophysi-
ology.Hence,neurodevelopmental aspects may be impor-
tant in some,but not all,forms of schizophrenia.
Limbic cortex
Experimental modalities beyond brain imaging have
advanced our understanding of the pathophysiology of
schizophrenia. These include postmortem tissue studies
and animal model experiments.Findings from postmortem
brain studies in schizophrenia are reviewed in this issue by
Harrison et al.
85 From the substantial body of postmortem
work reviewed, several guiding formulations emerge: (i)
the limbic system has been consistently identified as
affected in schizophrenia; and (ii) although the examina-
tion of postmortem transmitter systems has been skewed
toward the monoamines and dopamine in particular, it is
clear that many chemical systems are affected in schizo-
phrenia.
76 In accounting for a demonstrated abnormality,
separating cause and effect of the psychotic condition is
always critical and,at present,a matter of hypothesis.
In normal persons, phencyclidine (PCP) causes psy-
chotomimetic symptoms purportedly reminiscent of schiz-
ophrenia.PCP causes changes in experimental animals in
regional expression of immediate early genes (IEGs), a
marker of regional neuronal response to the drug.This
IEG response is interesting in that it is most potent in the
limbic cortex (hippocampus and anterior cingulate), and
it is long lasting,extending far beyond the drug half-life in
brain.To understand the underlying neurochemistry, we
have studied glutamate receptor response as a marker of
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345glutamate-mediated transmission.In response to PCP,the
NR1 subunit of the NMDA-sensitive glutamate receptor
shows a significant and sustained elevation in rat hip-
pocampus, especially in CA1, the last hippocampal sub-
field of the perforant pathway, suggesting reduced gluta-
matergic transmission at this synapse in response to PCP.
We interpreted these data to mean that a psy-
chotomimetic compound like PCP can decrease gluta-
matergic transmission in hippocampus, thus critically
interfering with hippocampal function. Since the hip-
pocampus is a brain region already known from post-
mortem studies in schizophrenia to be abnormal,
85 these
conclusions seemed plausible.Our own postmortem find-
ings,most importantly including a decrease in NR1expres-
sion in the schizophrenic hippocampus,
86 are consistent
with this current formulation.Moreover,our examination
of the human hippocampus in schizophrenia using func-
tional imaging techniques is largely consistent with this
formulation of abnormal hippocampal function drawn
from these animal and postmortem data.
Working hypothesis
We would like to suggest a working hypothesis of reduced
glutamatergic transmission at the NMDA receptor in the
hippocampus in schizophrenia, of greatest degree in the
CA1 area at the end of the perforant pathway and feeding
into the efferent structures of the subiculum.As a conse-
quence, one might expect a failure of both feed-forward
excitation and feed-forward inhibition,each in distinct sit-
uations.One might interpret the high resting rCBF in the
hippocampus as a failure of feed-forward inhibition (ie,a
lack of glutamatergic excitation of the inhibitory gamma-
aminobutyric acid [GABA]–ergic systems), while the
heightened sensitivity of hippocampal rCBF to ketamine
inhibition could be due to the abnormal composition of
the NMDA receptor in the illness and an overinhibition of
the feed-forward excitation.
Future
The availability of the very new resource of the
sequenced human genome is challenging our field to
take advantage of this critical genetic information.Trac-
ing the genetic basis of the cerebral mechanisms that
might express a particular genetic defect in psychosis or
in a disease like schizophrenia will require specific infor-
mation about the human schizophrenic brain. Disease
formulations will be testable as models for the genetic
changes we will find in this illness.❏
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neuroimágenes han abierto el cerebro esquizo-
frénico a investigaciones directas en términos de
estructura, neuroquímica y función. Entre los nue-
vos propósitos diagnósticos está el agrupar la
esquizofrenia junto con los trastornos de perso-
nalidad relacionados con esquizofrenia en la
misma entidad nosológica y llamar a este trastor-
no espectro esquizofrénico. Las nuevas hipótesis
de la fisiopatología no desconocen el papel prin-
cipal de la dopamina, pero enfatizan la participa-
ción de sistemas de integración neural en la
expresión de la enfermedad y del sistema límbico
en la generación de los síntomas. A partir de la
genética molecular combinada con hipótesis
generadas en experimentos que utilicen neuroi-
mágenes y tejidos humanos post mortem, proba-
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futuros descubrimientos.
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La schizophrénie est une maladie dont les signes
et les symptômes cliniques, l’évolution et les
caractéristiques cognitives sont bien décrits. Des
traitements efficaces existent même s'ils ne sont
vraisemblablement que palliatifs. Néanmoins, ce
vaste champ de connaissances n’a pas encore per-
mis d’établir la physiopathologie ou l’étiologie de
la schizophrénie. Les facteurs de risque les plus
évidents de la schizophrénie sont génétiques et
les scientifiques fondent les plus grands espoirs
sur les nouvelles acquisitions relatives au génome
humain pour faire progresser la connaissance du
mécanisme pathologique. L’imagerie cérébrale a
ouvert la voie aux investigations directes en
termes de structure, neurochimie et fonction du
cerveau schizophrène. De nouveaux cadres dia-
gnostiques ont été proposés, à l'instar de l'entité
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ne fait pas de doute que la génétique moléculai-
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